Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Drug Metabolism and Pharmacokinetics
|
July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2a
Tomohisa Saito, Satofumi Iida, Takehiko Kawanishi
The Journal of Pharmacy and Pharmacology
|
December 16, 2010
Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation
Satofumi Iida, Takehiko Kawanishi, Masahiro Hayashi
International Journal of Clinical Pharmacology and Therapeutics
|
April 25, 2015
Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietin
Kiyohiko Nakai, Kumiko Miyata, Satofumi Iida, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
October 7, 2011
Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial
Tomonori Kamei, Takahide Uchimura, Kazuhiro Nishimiya, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 4, 2009
The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults
Satofumi Iida, Haruki Kinoshita, Takehiko Kawanishi, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
December 6, 2014
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
Kiyohiko Nakai, Masato Tobinai, Junko Hashimoto, et al.
Clinical Pharmacokinetics
|
November 19, 2014
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment
Kiyohiko Nakai, Satofumi Iida, Masato Tobinai, et al.
Drug Metabolism and Pharmacokinetics
|
January 15, 2014
Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patients
Kiyohiko Nakai, Russell Wada, Satofumi Iida, et al.
The Journal of Pharmacy and Pharmacology
|
July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor
Tomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 17, 2005
The determination of 2beta-(3-hydroxypropoxy)-1alpha,25-dihydroxy vitamin D3 (ED-71) in human serum by high-performance liquid chromatography-electrospray tandem mass spectrometry
Naoaki Murao, Norihisa Ohishi, Yoshiaki Nabuchi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Drug Metabolism and Pharmacokinetics
|
July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2a
Tomohisa Saito, Satofumi Iida, Takehiko Kawanishi
The Journal of Pharmacy and Pharmacology
|
December 16, 2010
Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation
Satofumi Iida, Takehiko Kawanishi, Masahiro Hayashi
International Journal of Clinical Pharmacology and Therapeutics
|
April 25, 2015
Effective use of modeling and simulation in designing bioequivalence and comparability studies of large-molecule compounds: the case of erythropoietin
Kiyohiko Nakai, Kumiko Miyata, Satofumi Iida, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
October 7, 2011
Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial
Tomonori Kamei, Takahide Uchimura, Kazuhiro Nishimiya, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 4, 2009
The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults
Satofumi Iida, Haruki Kinoshita, Takehiko Kawanishi, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
December 6, 2014
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
Kiyohiko Nakai, Masato Tobinai, Junko Hashimoto, et al.
Clinical Pharmacokinetics
|
November 19, 2014
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment
Kiyohiko Nakai, Satofumi Iida, Masato Tobinai, et al.
Drug Metabolism and Pharmacokinetics
|
January 15, 2014
Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patients
Kiyohiko Nakai, Russell Wada, Satofumi Iida, et al.
The Journal of Pharmacy and Pharmacology
|
July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor
Tomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 17, 2005
The determination of 2beta-(3-hydroxypropoxy)-1alpha,25-dihydroxy vitamin D3 (ED-71) in human serum by high-performance liquid chromatography-electrospray tandem mass spectrometry
Naoaki Murao, Norihisa Ohishi, Yoshiaki Nabuchi, et al.
Page
of 2